{"id":4931,"date":"2018-03-20T17:40:17","date_gmt":"2018-03-20T16:40:17","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/03\/20180320_CP_Adisseo_Seventure_LancementVF.pdf"},"modified":"2018-03-20T17:40:17","modified_gmt":"2018-03-20T16:40:17","slug":"20180320_cp_adisseo_seventure_lancementvf","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-launches-european-clinical-trial-in-severe-acute-graft-versus-host-disease-for-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation-2\/20180320_cp_adisseo_seventure_lancementvf\/","title":{"rendered":"20180320_CP_Adisseo_Seventure_LancementVF"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-4931","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n